SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?

Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis.
Read the full report on Asianet Newsable
Story file
- Section
- India
- First reported by
- Asianet Newsable
- Reporter
- stocktwits inc
- Published
- Tuesday, 13 October 2026, 4:00 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.






